Clinical Trial Update: A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating crovalimab for antiphospholipid syndrome has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antiphospholipid Syndrome

Drugs mentioned

• Crovalimab (crovalimab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Antiphospholipid Syndrome | Phase 2 | Status: WITHDRAWN